KYMR
Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$118.18
+0.76%Margins
Gross margin
102.0%
EBITDA margin
-278.8%
EBIT margin
-333.5%
Net margin
-285.4%
FCF margin
-226.6%
-19.9%
Return on equity
-18.2%
Return on assets
-22.0%
Return on invested capital
0.06x
Asset turnover
-$236.8M
Cash from operations
$8.31
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026